Concentration in a small number of products
Business prospects depend heavily on a few approved TTFields indications.
- Scope
- Optune Gio, Optune Lua, Optune Pax
- Materiality
- high
NovoCure Ltd
NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients. The company is headquartered in the United States and serves oncology markets across the U.S., Europe, Japan, and other international markets through direct and partner-based distribution.
−21,2 %
74,5 %
−20,8 %
+8,3 %
2.90
2.71
| % | |
|---|---|
| TTFields oncology devices | 85% Portable tumor-treating field systems used to deliver therapy for approved cancer indications. |
| Consumable arrays and accessories | 10% Replacement arrays and related consumables used with the therapy devices. |
| Patient support and service programs | 5% Training, onboarding, and support services that help patients use the therapy at home. |
NovoCure sells primarily to oncology patients through healthcare providers, with therapy adoption driven by physicians...
- Glioblastoma patientsprimary
Patients with GBM treated with Optune Gio, typically through neuro-oncology and oncology centers.
- NSCLC patientsprimary
Patients with non-small cell lung cancer treated with Optune Lua in approved markets.
- Pancreatic cancer patientsprimary
Patients with pancreatic cancer treated with Optune Pax in the U.S. and other approved markets.
- Hospitals and channel partnerssecondary
Hospitals and local partners that distribute the product and support patient onboarding in some countries.
NovoCure is a U.S.-based company with revenue generated across the United States and a broad international footprint,...
- •United States is a core market for approved indications and reimbursement
- •France and Germany are important European revenue contributors
- •Other international markets contribute through active patient growth
- •Greater China is commercialized through a Zai collaboration
- •Japan uses hospital-based distribution rather than direct-to-patient
NovoCure’s strategy centers on expanding adoption of TTFields in approved indications while pursuing additional...
01
Increase adoption in approved indicationsshort-term
Revenue depends on patient starts and continued use of TTFields therapy.
02
Broaden regulatory approvals and market accessmedium-term
New indications and reimbursement pathways expand the addressable market.
03
Scale global commercialization through partners and trainingmedium-term
The therapy requires physician certification and local market execution.
NovoCure is exposed to regulatory, reimbursement, and commercialization risk because its products require approval,...
Regulatory and reimbursement delays
Adoption depends on approvals and payer coverage in each market.
- Scope
- New indications and international expansion
- Materiality
- high
Single-source supply dependence
Loss of a supplier could delay shipments or clinical studies.
- Scope
- Components and manufactured parts
- Materiality
- high
Cybersecurity and patient data exposure
The company handles sensitive patient treatment and health information.
- Scope
- Connected therapy systems and third-party hosting
- Materiality
- medium
Partner execution risk
Some markets rely on collaborators that control commercialization efforts.
- Scope
- Greater China and selected distribution markets
- Materiality
- medium
Revenue recognition
Can affect timing and comparability of reported revenue
Inventory obsolescence
Affects cost of revenues and gross margin
Service pool equipment and operating leases
Affects balance sheet assets and operating expenses
Impairment of long-lived assets
May create non-cash charges
Uncertain tax positions
Can change tax expense and liabilities
NextCure, Inc.
NXTC · Pharmaceutical Preparations
OnKure Therapeutics, Inc.
OKUR · Pharmaceutical Preparations
EXICURE, INC.
XCUR · Pharmaceutical Preparations
NEONC TECHNOLOGIES HOLDINGS, INC.
NTHI · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Evommune, Inc.
EVMN · Pharmaceutical Preparations
: 29/04/2026